ReviewPharmacoEconomics2016

Vedolizumab for Treating Moderately to Severely Active Crohn's Disease After Prior Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Rachid Rafia et al.PubMed ↗Publisher ↗

No numbers read from the abstract.